Cliff Asness's CPRX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 228,351 shares of Catalyst Pharmaceuticals, Inc. (CPRX) worth $5.65 M, representing 0.00% of the portfolio. First purchased in 2013-Q4, this long-term strategic position has been held for 45 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in CPRX, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2019, adding 968,574 shares. Largest reduction occurred in Q2 2018, reducing 427,301 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Catalyst Pharmaceuticals (CPRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Catalyst Pharmaceuticals (CPRX) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -75,300 | Reduce 24.80% | 228,351 | $24.76 |
| Q4 2025 | -33,401 | Reduce 9.91% | 303,651 | $23.34 |
| Q3 2025 | -61,370 | Reduce 15.40% | 337,052 | $19.70 |
| Q2 2025 | -47,088 | Reduce 10.57% | 398,422 | $21.70 |
| Q1 2025 | -31,501 | Reduce 6.60% | 445,510 | $24.25 |
| Q4 2024 | +17,659 | Add 3.84% | 477,011 | $20.87 |
| Q3 2024 | -29,034 | Reduce 5.94% | 459,352 | $19.88 |
| Q2 2024 | +227,321 | Add 87.07% | 488,386 | $15.49 |
| Q1 2024 | -81,736 | Reduce 23.84% | 261,065 | $15.94 |
| Q4 2023 | -133,999 | Reduce 28.10% | 342,801 | $16.81 |
| Q3 2023 | -166,194 | Reduce 25.85% | 476,800 | $11.69 |
| Q2 2023 | +378,770 | Add 143.35% | 642,994 | $13.44 |
| Q1 2023 | +35,794 | Add 15.67% | 264,224 | $16.58 |
| Q4 2022 | -172,201 | Reduce 42.98% | 228,430 | $18.60 |
| Q3 2022 | -86,910 | Reduce 17.83% | 400,631 | $12.83 |
| Q2 2022 | +73,989 | Add 17.89% | 487,541 | $7.01 |
| Q1 2022 | -24,521 | Reduce 5.60% | 413,552 | $8.29 |
| Q4 2021 | -37,244 | Reduce 7.84% | 438,073 | $6.77 |
| Q3 2021 | +151,119 | Add 46.61% | 475,317 | $5.30 |
| Q2 2021 | -399,455 | Reduce 55.20% | 324,198 | $5.75 |
| Q1 2021 | -269,778 | Reduce 27.16% | 723,653 | $4.61 |
| Q4 2020 | +143,899 | Add 16.94% | 993,431 | $3.34 |
| Q3 2020 | -55,712 | Reduce 6.15% | 849,532 | $2.97 |
| Q2 2020 | -307,205 | Reduce 25.34% | 905,244 | $4.62 |
| Q1 2020 | +77,305 | Add 6.81% | 1.21 M | $3.85 |
| Q4 2019 | +968,574 | Add 581.48% | 1.14 M | $3.75 |
| Q3 2019 | -113,868 | Reduce 40.60% | 166,570 | $5.31 |
| Q2 2019 | +217,841 | Add 348.01% | 280,438 | $3.84 |
| Q1 2019 | -77,245 | Reduce 55.24% | 62,597 | $5.10 |
| Q4 2018 | -58,754 | Reduce 29.58% | 139,842 | $1.92 |
| Q3 2018 | -176,800 | Reduce 47.10% | 198,596 | $3.78 |
| Q2 2018 | -427,301 | Reduce 53.23% | 375,396 | $3.12 |
| Q1 2018 | +466,119 | Add 138.49% | 802,697 | $2.39 |
| Q4 2017 | -16,048 | Reduce 4.55% | 336,578 | $3.91 |
| Q3 2017 | +352,626 | New Buy | 352,626 | $2.52 |
| Q1 2016 | -63,742 | Sold Out | 0 | $0.00 |
| Q4 2015 | -75,820 | Reduce 54.33% | 63,742 | $2.45 |
| Q3 2015 | -45,220 | Reduce 24.47% | 139,562 | $3.00 |
| Q1 2015 | -26,100 | Reduce 12.38% | 184,782 | $4.33 |
| Q4 2014 | -29,400 | Reduce 12.24% | 210,882 | $2.97 |
| Q2 2014 | +39,000 | Add 19.38% | 240,282 | $2.53 |
| Q1 2014 | +51,600 | Add 34.47% | 201,282 | $2.26 |
| Q4 2013 | +149,682 | New Buy | 149,682 | $1.95 |
Cliff Asness's Catalyst Pharmaceuticals Investment FAQs
Cliff Asness first purchased Catalyst Pharmaceuticals, Inc. (CPRX) in Q4 2013, acquiring 149,682 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Catalyst Pharmaceuticals, Inc. (CPRX) for 45 quarters since Q4 2013.
Cliff Asness's largest addition to Catalyst Pharmaceuticals, Inc. (CPRX) was in Q4 2019, adding 1,135,144 shares worth $4.26 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 228,351 shares of Catalyst Pharmaceuticals, Inc. (CPRX), valued at approximately $5.65 M.
As of the Q1 2026 filing, Catalyst Pharmaceuticals, Inc. (CPRX) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Catalyst Pharmaceuticals, Inc. (CPRX) was 1,212,449 shares, as reported at the end of Q1 2020.